Individualized Duration of Dual Antiplatelet Therapy Guided by Risk Scores - Ready for Prime Time? -
- 1 February 2020
- journal article
- editorial
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 84 (2), 153-155
- https://doi.org/10.1253/circj.CJ-19-1149
Abstract
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societiesThis publication has 7 references indexed in Scilit:
- Efficacy and Safety of Guideline-Recommended Risk Score-Directed Dual Antiplatelet Therapy After 2nd-Generation Drug-Eluting StentsCirculation Journal, 2020
- Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigmsExpert Opinion on Drug Safety, 2019
- ACC/AHA Versus ESC Guidelines on Dual Antiplatelet TherapyJournal of the American College of Cardiology, 2018
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal, 2018
- Dual antiplatelet therapy after coronary stentingExpert Opinion on Pharmacotherapy, 2016
- Duration of Dual Antiplatelet Therapy After Coronary StentingJournal of the American College of Cardiology, 2015
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting StentsNew England Journal of Medicine, 2014